Financings Of The Fortnight Follows The Money Wherever It Goes
This article was originally published in The Pink Sheet Daily
Are VCs looking beyond biopharma to put money into areas like health services and diagnostics? Plus updates on Castlight, Agile Therapeutics, Otonomy, and more.
You may also be interested in...
The health care cost transparency firm, which has raised $181 million to date, hopes to grow its commercialization team, add features to its service and expand its reach.
Agile said in 2008 its lead product was ready for Phase III trials. Those trials might start soon, now that the firm has found new backers.
Genzyme CEO and Chairman Termeer highlighted investor day presentation with five-point plan for enhancing shareholder value, including $2 billion stock repurchase plan.